Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Study Summary

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Conditions

KRAS G12C Mutant Solid Tumors Carcinoma, Non-Small Cell Lung Carcinoma, Non-Small-Cell Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Carcinoma Nonsmall Cell Lung Cancer Colorectal Cancer Colorectal Carcinoma Colorectal Neoplasms Colorectal Tumors Neoplasms, Colorectal

Interventions / Drugs

JDQ443 trametinib Ribociclib cetuximab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment74 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.152091+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.